AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34063304 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 42
Study 34063304 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 34433379 — intervention group
Group type: EXPERIMENTAL
Intervention: VaLiANT intervention (group-based intervention for valued living)
Number of subjects: 8
Study 32468669 — intervention group
Group type: EXPERIMENTAL
Intervention: Health belief model-based education and acupressure
Number of subjects: 163
Study 32468669 — intervention group
Group type: EXPERIMENTAL
Intervention: Health belief model-based education only
Number of subjects: 163
Study 32468669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 163
Study 34597729 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg intravenously at weeks 0, 2, 6, 14, and 22 (VDZ)
Number of subjects: 32
Study 34597729 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg intravenously at weeks 0, 2, 6, 14, and 22 plus an additional dose at week 10 (VDZ + wk10)
Number of subjects: 32
Study 34597729 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vedolizumab regimens
Number of subjects: 32
Study 34406312 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) users
Number of subjects: 690
Study 34406312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic-dose LMWH users
Number of subjects: 690
Study 34406312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose LMWH users (based on biomarkers)
Number of subjects: 690
Study 34406312 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of anticoagulants
Number of subjects: 690
Study 34406312 — intervention group
Group type: EXPERIMENTAL
Intervention: All LMWH users
Number of subjects: 690
Study 34406312 — intervention group
Group type: EXPERIMENTAL
Intervention: Major hemorrhage
Number of subjects: 690
Study 34406312 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolism
Number of subjects: 690
Study 33655601 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35065602 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed (TH) ECC
Number of subjects: 35
Study 35065602 — intervention group
Group type: COMPARATOR
Intervention: One-handed (OH) ECC
Number of subjects: 35
Study 32757418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet-tasting solution
Number of subjects: 56
Study 32757418 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (Control)
Number of subjects: 56
Study 35040873 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program
Number of subjects: 0
Study 35040873 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33118688 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on traditional risk factors, biomarkers, and variabilities in fasting plasma glucose, HbA1c, and blood pressure.
Number of subjects: 9692
Study 33118688 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for expanded cardiovascular-specific mortality.
Number of subjects: 9692
Study 35285143 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminder (alert group)
Number of subjects: 13000
Study 35285143 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13000
Study 35285143 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert group
Number of subjects: 13000
Study 34271362 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40 mg BID) + innovative pelvic floor muscle training (iPFMT) with lumbopelvic stabilization
Number of subjects: 158
Study 34271362 — intervention group
Group type: COMPARATOR
Intervention: Oral duloxetine treatment (40 mg BID)
Number of subjects: 158
Study 32524641 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective recruitment protocol
Number of subjects: 0
Study 32524641 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected cohorts
Number of subjects: 0
Study 34342023 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversized postcard intervention promoting water testing with a free water test offer
Number of subjects: 0
Study 34342023 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversized postcard intervention promoting water testing without a free water test offer
Number of subjects: 0
Study 34342023 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 0
Study 34019549 — intervention group
Group type: EXPERIMENTAL
Intervention: Op/eds defending impartiality of truth-seekers
Number of subjects: 0
Study 34019549 — intervention group
Group type: EXPERIMENTAL
Intervention: Video op/ed exposure
Number of subjects: 0
Study 34019549 — intervention group
Group type: COMPARATOR
Intervention: Text op/ed availability
Number of subjects: 0
Study 32253184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 16 mg
Number of subjects: 303
Study 32253184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 64 mg
Number of subjects: 303
Study 32253184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 32253184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg
Number of subjects: 303
Study 32253184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg
Number of subjects: 303
Study 32253184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (all doses)
Number of subjects: 303
Study 35635233 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT-based screening (invited group)
Number of subjects: 897812
Study 35635233 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT-based screening (participating group)
Number of subjects: 897812
Study 35635233 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT-based screening (male participants aged 60-71 years)
Number of subjects: 897812
Study 35635233 — intervention group
Group type: COMPARATOR
Intervention: Not-yet-invited group (control)
Number of subjects: 897812
Study 32533243 — intervention group
Group type: EXPERIMENTAL
Intervention: ANODAL tDCS
Number of subjects: 14
Study 32533243 — intervention group
Group type: COMPARATOR
Intervention: CATHODAL tDCS
Number of subjects: 14
Study 32533243 — intervention group
Group type: COMPARATOR
Intervention: SHAM tDCS
Number of subjects: 14
Study 35379598 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg intravenous tocilizumab (Group 1)
Number of subjects: 37
Study 35379598 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg intravenous tocilizumab (Group 2)
Number of subjects: 37
Study 35379598 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of intravenous tocilizumab
Number of subjects: 37
Study 33454995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 0
Study 33454995 — intervention group
Group type: COMPARATOR
Intervention: Combined Oral Contraceptives (COCs)
Number of subjects: 0
Study 32374352 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-aging mobile app Sunface intervention
Number of subjects: 1573
Study 32374352 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1573
Study 34518968 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (controlled temperature management to 35°C prior to dura opening followed by 33°C for 48 hours)
Number of subjects: 32
Study 34518968 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37°C)
Number of subjects: 32
Study 34518968 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 32
Study 34518968 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 32
Study 34044355 — intervention group
Group type: EXPERIMENTAL
Intervention: I-Gel®
Number of subjects: 23
Study 34044355 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve-mask
Number of subjects: 23
Study 35522981 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous moderate‐intensity exercise (CMIE)
Number of subjects: 20
Study 35522981 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity interval exercise (HIIE)
Number of subjects: 20
Study 35522981 — intervention group
Group type: COMPARATOR
Intervention: CMIE and HIIE
Number of subjects: 20
Study 35840980 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) goggles and headphones during plaster removal or replacement
Number of subjects: 270
Study 35840980 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 270
Study 33792726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Number of subjects: 92
Study 33792726 — intervention group
Group type: COMPARATOR
Intervention: Flexion exercises
Number of subjects: 92
Study 32399799 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) facilitated conversation and Advance directive completion (n=155 dyads)
Number of subjects: 449
Study 32399799 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=68 dyads) with Developmental/relationship history and Nutrition/exercise tips
Number of subjects: 449
Study 32399799 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP)
Number of subjects: 449
Study 35046189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation (IMF) screw therapy
Number of subjects: 300
Study 35046189 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Number of subjects: 300
Study 35046189 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intraarticular saline injection)
Number of subjects: 300
Study 32345561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl
Number of subjects: 186
Study 32345561 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac
Number of subjects: 186
Study 33186393 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x 30 s Wingate sprints in hypoxia (3,000 m)
Number of subjects: 10
Study 33186393 — intervention group
Group type: COMPARATOR
Intervention: 6 x 30 s Wingate sprints at sea-level and up to 2,150 m
Number of subjects: 10
Study 33186393 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x 30 s Wingate sprints at 2,150 m
Number of subjects: 10
Study 36026477 — intervention group
Group type: COMPARATOR
Intervention: Unrefined maize porridge with [58Fe]SO4
Number of subjects: 20
Study 33757503 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Training
Number of subjects: 67
Study 33757503 — intervention group
Group type: COMPARATOR
Intervention: See One, Do One
Number of subjects: 67
Study 32173375 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120 trimers bound to BLPs delivered via intranasal (i.n.) drip
Number of subjects: 0
Study 33131314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP <120 mm Hg)
Number of subjects: 4678
Study 35863498 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation (2 or more passes)
Number of subjects: 127
Study 35863498 — intervention group
Group type: COMPARATOR
Intervention: Aquablation (1 pass)
Number of subjects: 127
Study 34528337 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (7 days of omeprazole + amoxicillin followed by 7 days of omeprazole + clarithromycin + metronidazole)
Number of subjects: 61
Study 34528337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 61
Study 33089699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 112
Study 33089699 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 35852693 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic silicone occlusive sheeting
Number of subjects: 61
Study 35852693 — intervention group
Group type: COMPARATOR
Intervention: Silicone occlusive sheeting
Number of subjects: 61
Study 34289038 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab-based therapies
Number of subjects: 0
Study 34289038 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab-based therapies with ≥CR and MRD negativity
Number of subjects: 0
Study 34289038 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 36478192 — intervention group
Group type: EXPERIMENTAL
Intervention: Active distraction using video games on a tablet device and wireless joystick (VG)
Number of subjects: 105
Study 36478192 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive distraction using video on tablet and wireless headphones (AV)
Number of subjects: 105
Study 36478192 — intervention group
Group type: COMPARATOR
Intervention: Basic behavior guidance technique Tell Show Do (C)
Number of subjects: 105
Study 33169240 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 10 mg/kg/12h IV for 6 weeks plus supportive measures
Number of subjects: 80
Study 33169240 — intervention group
Group type: COMPARATOR
Intervention: Supportive measures only (Control group)
Number of subjects: 80
Study 35575420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin in amorphous form
Number of subjects: 16
Study 35575420 — intervention group
Group type: COMPARATOR
Intervention: Ertugliflozin in cocrystal form
Number of subjects: 16
Study 34750484 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVI (interventional valve implantation into the inferior vena cava using an Edwards Sapien XT valve)
Number of subjects: 28
Study 34750484 — intervention group
Group type: COMPARATOR
Intervention: OMT (optimal medical therapy)
Number of subjects: 28
Study 32597035 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk Fat Globule Membrane (MFGM) supplementation (n=12)
Number of subjects: 25
Study 32597035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) (n=12)
Number of subjects: 25
Study 32455493 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehydration with 1.5 L of water within 1 hour before uroflowmetry
Number of subjects: 74
Study 32455493 — intervention group
Group type: COMPARATOR
Intervention: Non-prehydrated group
Number of subjects: 74
Study 32455493 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehydration
Number of subjects: 74
Study 32103603 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous skin cell suspension (ASCS) + compression therapy
Number of subjects: 52
Study 32103603 — intervention group
Group type: COMPARATOR
Intervention: Standard compression therapy (Control)
Number of subjects: 52
Study 615704460 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of ALA administered to recipients and graft perfused with 600 mg of ALA 1 hour before surgery
Number of subjects: 26
Study 615704460 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study 34461131 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA decalcification
Number of subjects: 29
Study 34461131 — intervention group
Group type: COMPARATOR
Intervention: Control samples
Number of subjects: 29
Study 32948109 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 145
Study 32948109 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia severity
Number of subjects: 145
Study 32948109 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 145
Study 34769925 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-based multi-ingredient supplementation (CMS)
Number of subjects: 14
Study 34524631 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (8-week program, delivered virtually via Zoom)
Number of subjects: 44
Study 34524631 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 44
Study 35920936 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg ICG
Number of subjects: 64
Study 35920936 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg ICG
Number of subjects: 64
Study 35920936 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg ICG
Number of subjects: 64
Study 35920936 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg ICG
Number of subjects: 64
Study 33288495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 68
Study 32026759 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation cues
Number of subjects: 587
Study 32026759 — intervention group
Group type: EXPERIMENTAL
Intervention: Community cues
Number of subjects: 587
Study 32026759 — intervention group
Group type: COMPARATOR
Intervention: No cue control
Number of subjects: 587
Study 36127689 — intervention group
Group type: EXPERIMENTAL
Intervention: LyssnCBT
Number of subjects: 1875
Study 35348084 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimage-guided CEIs
Number of subjects: 45
Study 35348084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided CEIs
Number of subjects: 45
Study 35348084 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided CEIs
Number of subjects: 45
Study 35348084 — intervention group
Group type: COMPARATOR
Intervention: All groups (Nonimage, Ultrasonography, Fluoroscopy)
Number of subjects: 45
Study 35655234 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl Starch (HES) 130 solution (Volulyte 6%)
Number of subjects: 350
Study 35655234 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte solution (Ionolyte)
Number of subjects: 350
Study 35308505 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 3000 IU/d oral spray supplementation
Number of subjects: 125
Study 35308505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (xylitol, water, mint)
Number of subjects: 125
Study 35297721 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon arrays
Number of subjects: 131
Study 35297721 — intervention group
Group type: COMPARATOR
Intervention: Numerical information
Number of subjects: 131
Study 32638427 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser lancing device (LMT‐3000)
Number of subjects: 40
Study 32638427 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle lancet
Number of subjects: 40
Study 37071202 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 36
Study 37071202 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise program
Number of subjects: 36
Study 33620551 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of a multivitamin tablet with 150 μg of iodine
Number of subjects: 200
Study 33620551 — intervention group
Group type: COMPARATOR
Intervention: Daily intake of a multivitamin tablet without iodine
Number of subjects: 200
Study 32656994 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 coaching calls, buddy training, primary care provider progress reports
Number of subjects: 562
Study 32656994 — intervention group
Group type: COMPARATOR
Intervention: 24 coaching calls
Number of subjects: 562
Study 616619992 — intervention group
Group type: EXPERIMENTAL
Intervention: Female peer mentors
Number of subjects: 150
Study 616619992 — intervention group
Group type: COMPARATOR
Intervention: Male peer mentors
Number of subjects: 150
Study 616619992 — intervention group
Group type: COMPARATOR
Intervention: No mentors
Number of subjects: 150
Study 35523062 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming
Number of subjects: 30
Study 35523062 — intervention group
Group type: COMPARATOR
Intervention: Conventional Rehabilitation (CR)
Number of subjects: 30
Study 34602388 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen combined with alprostadil
Number of subjects: 0
Study 34602388 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35312650 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (group A)
Number of subjects: 153
Study 35312650 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (group B)
Number of subjects: 153
Study 35312650 — intervention group
Group type: COMPARATOR
Intervention: No drink (control group C)
Number of subjects: 153
Study 32233961 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 301
Study 32233961 — intervention group
Group type: COMPARATOR
Intervention: MPSV4
Number of subjects: 301
Study 33834354 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone sprinkle 24 μg BID
Number of subjects: 522
Study 33834354 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone capsule 24 μg BID
Number of subjects: 522
Study 33834354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 522
Study 32980142 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 5 μg.mL−1 (n = 40)
Number of subjects: 160
Study 32980142 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 5 μg.mL−1 (n = 40)
Number of subjects: 160
Study 32980142 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 μg.mL−1 (n = 40)
Number of subjects: 160
Study 32980142 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusions (n = 40)
Number of subjects: 160
Study 35771219 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based leg heat therapy (HT) using water-circulating trousers, 90 min/session, 7 days/week for 8 weeks
Number of subjects: 34
Study 35771219 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 34
Study 34795398 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered wound assessment tool
Number of subjects: 492
Study 35918716 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D printed models during lectures
Number of subjects: 16
Study 35918716 — intervention group
Group type: COMPARATOR
Intervention: Didactic lectures only
Number of subjects: 16
Study 37005698 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week education and tailored exercise intervention (TEMPO)
Number of subjects: 50
Study 37005698 — intervention group
Group type: COMPARATOR
Intervention: Usual care and written information
Number of subjects: 50
Study 32912633 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix 10 mg
Number of subjects: 403
Study 32912633 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix 20 mg
Number of subjects: 403
Study 32912633 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix 40 mg
Number of subjects: 403
Study 32912633 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin 3.75 mg
Number of subjects: 403
Study 32912633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 37498273 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily step count
Number of subjects: 425
Study 37498273 — intervention group
Group type: EXPERIMENTAL
Intervention: Floors climbed
Number of subjects: 425